Skip To Main Content
Yogindra Vedvyas on Muck Rack

Yogindra Vedvyas

As seen in: Nature, MDPI, The Journal of Clinical Investigation
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile
Back to Yogindra Vedvyas’s profile

Articles by Yogindra Vedvyas

Affinity-tuned mesothelin CAR T cells demonstrate enhanced targeting specificity and reduced off-tumor toxicity

|
By JCI Insight, Yanping Yang, Yogindra Vedvyas, Yago Alcaina
| The Journal of Clinical Investigation
Abstract The application of chimeric antigen receptor (CAR) T cell therapy in solid tumors is hindered by life-threatening toxicities resulting from on-target, off-tumor killing of nonmalignant cells that express low levels of the target antigen. Mesothelin (MSLN) has been identified as a target antigen for CAR T cell treatment of mesothelioma, lung, ovarian, and other cancers because of its high expression on tumor cells and limited expression on mesothelial cells.
Open in Who Shared Issue with article?

Chimeric Antigen Receptor T Cell Therapy Targeting Epithelial Cell Adhesion Molecule in Gastric Cancer: Mechanisms of Tumor Resistance

|
By Yanping Yang, Raymond Louie, Yogindra Vedvyas, Janusz Puc
| MDPI
All articles published by MDPI are made immediately available worldwide under an open access license. No special permission is required to reuse all or part of the article published by MDPI, including figures and tables. For articles published under an open access Creative Common CC BY license, any part of the article may be reused without permission provided that the original article is clearly cited. For more information, please refer to https://www.mdpi.com/openaccess.
Open in Who Shared Issue with article?

Publisher Correction: Manufacturing and preclinical validation of CAR T cells targeting ICAM-1 for advanced thyroid cancer therapy

|
By Thomas Fahey, Yogindra Vedvyas, Jaclyn E McCloskey, Yen-Michael S. Hsu
| Nature Verified
Correction to: Scientific Reports https://doi.org/10.1038/s41598-019-46938-7, published online 23 July 2020. In the original version of this Article, the author Koen van Besien was incorrectly indexed. This error has now been corrected. Author information Affiliations Department of Radiology, Molecular Imaging Innovations Institute, New York, NY, 10065, USA Yogindra Vedvyas, Jaclyn E. McCloskey, Yanping Yang & Moonsoo M. Jin Department of Surgery, New York, NY, 10065, USA Irene M. Min, Thomas J.
Open in Who Shared Issue with article?

A fluorescent, [18F]-positron-emitting agent for imaging PMSA allows genetic reporting in adoptively-transferred, genetically-modified cells

|
By Hua Guo, Kommidi Harikrishna, Yogindra Vedvyas, Jaclyn E McCloskey
| American Chemical Society
Abstract Clinical trials that involve genome-edited-cells are growing in popularity, where CAR-T immunotherapy and CRISPR editing are more recognized strategies. Genetic reporters are needed to localize the molecular events that these cells cause in patients. Specifically, a non-immunogenic genetic reporter is urgently needed as current reporters are immunogenic due to derivation from non-human sources.
Open in Who Shared Issue with article?
Show More